Unlocking Long-Term Success: Insights From 5-Year Follow-Up of the CAPTIVATE Trial in CLL/SLL

Paolo Ghia, MD, PhD, discusses long-term efficacy data for fixed-duration ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia.

Related Keywords

Italy ,Milan ,Lombardia ,San Diego ,California ,United States ,Paolo Ghia ,Division Of Experimental Oncology ,Strategic Research Program ,San Raffaele Scientific Institute ,Experimental Oncology ,B Cell Neoplasia Unit ,Vita Salute San ,D ,Phd ,